Immunic, Inc. to Report Q2 2024 Financial Results and Corporate Update

Immunic, Inc., a biotechnology firm focused on developing oral small molecule therapies for chronic inflammatory and autoimmune diseases, announced plans to release its financial results for the second quarter ending June 30, 2024. This announcement, scheduled for August 8, 2024, will also include a corporate update and will precede the opening of the U.S. financial markets. Following the release, there will be a webcast at 8:00 am ET to discuss the results and updates further.

Participants interested in joining the webcast are encouraged to register in advance through Immunic's official website. Upon registration, participants will receive a confirmation email that includes a link for online access or a phone number for those who prefer to dial in. Additionally, an archived replay of the webcast will be made available approximately an hour after the event concludes and can be accessed on Immunic's website.

Immunic, Inc. (Nasdaq: IMUX) is making significant strides in the biotechnology field, particularly in the area of orally administered small molecule therapies aimed at combating chronic inflammatory and autoimmune diseases. The company's primary development program, vidofludimus calcium (IMU-838), is currently undergoing phase 3 and phase 2 clinical trials for treating relapsing and progressive multiple sclerosis, respectively. Vidofludimus calcium has demonstrated therapeutic activity in phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. This compound offers neuroprotective benefits as a first-of-its-kind nuclear receptor related 1 (Nurr1) activator, along with anti-inflammatory and antiviral properties by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).

Another promising candidate in Immunic's pipeline is IMU-856, which targets the protein Sirtuin 6 (SIRT6). This treatment aims to restore intestinal barrier function and regenerate bowel epithelium, potentially offering therapeutic benefits for various gastrointestinal diseases. IMU-856 is currently being prepared for a phase 2 clinical trial to treat conditions like celiac disease. Furthermore, IMU-381 is in preclinical testing stages, representing a next-generation molecule designed to cater specifically to gastrointestinal diseases.

Immunic, Inc. continues to prioritize innovation and development in its quest to address significant unmet medical needs in the realm of chronic inflammatory and autoimmune disorders. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!